Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,939,150
  • Shares Outstanding, K 107,611
  • Annual Sales, $ 509,340 K
  • Annual Income, $ -207,040 K
  • 60-Month Beta 0.71
  • Price/Sales 3.82
  • Price/Cash Flow N/A
  • Price/Book 5.56
Trade NVCR with:

Options Overview Details

View History
  • Implied Volatility 70.97% ( -0.97%)
  • Historical Volatility 74.61%
  • IV Percentile 42%
  • IV Rank 24.39%
  • IV High 139.14% on 03/25/24
  • IV Low 48.98% on 09/21/23
  • Put/Call Vol Ratio 0.65
  • Today's Volume 1,180
  • Volume Avg (30-Day) 890
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 36,677
  • Open Int (30-Day) 33,213

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.34
  • Number of Estimates 5
  • High Estimate -0.29
  • Low Estimate -0.38
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.10 +9.34%
on 09/03/24
20.21 -12.86%
on 08/30/24
-0.29 (-1.62%)
since 08/16/24
3-Month
15.85 +11.10%
on 07/08/24
23.87 -26.23%
on 07/30/24
-1.83 (-9.41%)
since 06/18/24
52-Week
10.87 +62.01%
on 11/13/23
24.74 -28.81%
on 05/20/24
-1.21 (-6.43%)
since 09/18/23

Most Recent Stories

More News
Why NovoCure Stock Dived by 13% This Week

Investors found the announced changes to the company's C-suite unsettling.

NVCR : 17.61 (-2.28%)
Chips, Glorious Chips!

Someone's gotta make 'em, and someone's gotta buy 'em.

AMD : 148.29 (-1.68%)
NVDA : 113.37 (-1.92%)
META : 537.95 (+0.30%)
MSFT : 430.81 (-1.00%)
GOOGL : 159.81 (+0.31%)
AMZN : 186.43 (-0.24%)
INTC : 20.77 (-3.26%)
ISRG : 482.09 (-0.25%)
DXCM : 69.46 (+0.75%)
GOOG : 160.81 (+0.33%)
PODD : 236.11 (+0.24%)
TNDM : 42.64 (-0.98%)
NovoCure (NVCR) Q2 2024 Earnings Call Transcript

NVCR earnings call for the period ending June 30, 2024.

NVCR : 17.61 (-2.28%)
NovoCure: Q2 Earnings Snapshot

NovoCure: Q2 Earnings Snapshot

NVCR : 17.61 (-2.28%)
NovoCure (NVCR) Q1 2024 Earnings Call Transcript

NVCR earnings call for the period ending March 31, 2024.

NVCR : 17.61 (-2.28%)
NovoCure: Q1 Earnings Snapshot

NovoCure: Q1 Earnings Snapshot

NVCR : 17.61 (-2.28%)
Why NovoCure Stock Soared 18.3% This Week

Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.

NVCR : 17.61 (-2.28%)
Why Novocure Stock Is Jumping Today

Novocure had good news mixed with some not-so-good news.

NVCR : 17.61 (-2.28%)
Stocks Settle Higher on Lower Bond Yields and Quarter-End Window Dressing

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.86%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.39%. Stock indexes...

$SPX : 5,618.26 (-0.29%)
SPY : 561.40 (-0.30%)
$DOWI : 41,503.10 (-0.25%)
DIA : 416.19 (-0.26%)
$IUXX : 19,344.49 (-0.45%)
QQQ : 471.44 (-0.43%)
ZNZ24 : 115-010 (-0.04%)
CTAS : 201.38 (-1.17%)
MRK : 118.64 (+0.30%)
MRVL : 71.55 (-1.68%)
EXR : 181.65 (+1.61%)
MDT : 88.13 (-0.56%)
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024

Stocks that traded heavily or had substantial price changes on Wednesday: Merck, Cintas rise; GameStop, MiMedx fall

NVCR : 17.61 (-2.28%)
NCNO : 29.88 (+0.54%)
JNJ : 166.15 (-0.55%)
MRK : 118.64 (+0.30%)
GME : 19.65 (-2.53%)
CTAS : 201.38 (-1.17%)
MKKGY : 36.8475 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 19.74
2nd Resistance Point 19.16
1st Resistance Point 18.39
Last Price 17.61
1st Support Level 17.04
2nd Support Level 16.46
3rd Support Level 15.69

See More

52-Week High 24.74
Fibonacci 61.8% 19.44
Fibonacci 50% 17.80
Last Price 17.61
Fibonacci 38.2% 16.17
52-Week Low 10.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar